Olivier Martinez
Director/Board Member at INNATE PHARMA
Profile
Currently, Olivier Martinez occupies the position of Chairman & Chief Executive Officer at Société d'Amenagement des Territoires & d'Equipement des, Chairman at SA Seridis and Investment Director at BPIFrance Investissement SAS.
He is also on the board of Innate Pharma SA, ABIONYX Pharma SA and Alizé Pharma SARL.
In the past Olivier Martinez occupied the position of Chairman of Cytheris SA, Partner at Bioam Gestion SA, Director-Investments & Member-Management Board at Bioam Gestion SA and Investment Director at CDC Croissance SA.
Dr. Martinez received a doctorate from Université de Paris XI Paris Sud, an undergraduate degree from École Normale Supérieure and an MBA from College des Ingenieurs.
Olivier Martinez active positions
Companies | Position | Start |
---|---|---|
ABIONYX PHARMA | Director/Board Member | - |
INNATE PHARMA | Director/Board Member | 2021-06-29 |
Société d'Amenagement des Territoires & d'Equipement des
Société d'Amenagement des Territoires & d'Equipement des Engineering & ConstructionIndustrial Services Société d'Amenagement des Territoires & d'Equipement des provides civil engineering construction work services. The private company is based in Saint-Paul-les-Dax, France. The French company was founded in 1963. The CEO is Olivier Martinez. | Chief Executive Officer | - |
SA Seridis
SA Seridis Food RetailRetail Trade Part of Confederation Nationale Crédit Mutuel SA, SA Seridis operates supermarkets. The private company is based in Saint-Seurin-sur-l'Isle, France and was founded in 1987. | Chairman | - |
BPIFrance Investissement SAS
BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Private Equity Investor | 2010-10-13 |
Alizé Pharma SARL | Director/Board Member | - |
Former positions of Olivier Martinez
Companies | Position | End |
---|---|---|
ADOCIA | Director/Board Member | 2022-11-30 |
INNATE PHARMA | Director/Board Member | 2016-06-01 |
CDC Croissance SA
CDC Croissance SA Investment ManagersFinance CDC Croissance SA is an asset management firm headquartered in Paris, France. It was founded in 2001 as CDC Entreprises Valeurs Moyennes SAS. The firm is a subsidiary of BPIFrance Investissement, which in turn is a subsidiary of government-owned Caisse d'Amortissement de la Dette Sociale. CDC Croissance manages assets of individual and institutional clients. | Chief Investment Officer | 2012-12-31 |
░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Olivier Martinez
École Normale Supérieure | Undergraduate Degree |
College des Ingenieurs | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
POXEL | Health Technology |
INNATE PHARMA | Health Technology |
ABIONYX PHARMA | Health Technology |
ADOCIA | Health Technology |
Private companies | 13 |
---|---|
Bioam Gestion SA
Bioam Gestion SA Investment ManagersFinance Bioam Gestion SA (BG) is a venture capital investment firm established in 2000 at the initiative of the French Ministry of Research and located in Paris. The firm invests capital from public and private sources. BG manages FCPR venture capital funds focused on the biotechnology sector. The firm's sponsors include the three French national research institutes: CNRS (fundamental research), INRA (agriculture-oriented research) and INSERM (medical research), as well as financial institutions such as CDC Enterprises, AXA Private Equity, a regional savings bank, and corporations. | Finance |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
Université de Paris XI Paris Sud | Consumer Services |
BPIFrance Investissement SAS
BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Finance |
CDC Croissance SA
CDC Croissance SA Investment ManagersFinance CDC Croissance SA is an asset management firm headquartered in Paris, France. It was founded in 2001 as CDC Entreprises Valeurs Moyennes SAS. The firm is a subsidiary of BPIFrance Investissement, which in turn is a subsidiary of government-owned Caisse d'Amortissement de la Dette Sociale. CDC Croissance manages assets of individual and institutional clients. | Finance |
Genticel SA
Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France. | Health Technology |
Millendo Therapeutics SAS
Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Health Technology |
FAB Pharma SAS
FAB Pharma SAS Miscellaneous Commercial ServicesCommercial Services FAB Pharma SAS operates as a biopharmaceutical company. It develops drugs for the treatment of bacterial infections. It also provides pharmaceutical research services. It focuses on therapeutics addressing current antibiotics resistance issues to control severe bacterial infections. Its products are drugs with low-molecular-weight antibacterial molecules for enzymes in Fatty Acid Biosynthesis I. The company was founded by Stefan Fischer on June 15, 2009 and is headquartered in Paris, France. | Commercial Services |
SA Seridis
SA Seridis Food RetailRetail Trade Part of Confederation Nationale Crédit Mutuel SA, SA Seridis operates supermarkets. The private company is based in Saint-Seurin-sur-l'Isle, France and was founded in 1987. | Retail Trade |
HalioDx SASU
HalioDx SASU BiotechnologyHealth Technology Part of HalioDxinvest SAS, HalioDx SASU is a French company that offers a comprehensive suite of biomarker services to deliver integrated and interpreted data, uncovering the critical biomarkers that drive effective decision-making. The private company is based in Marseille, France. The company's services include outsourcing assays such as NGS, qPCR, ELISA, IHC, and IVD testing to Veracyte. The company also offers Immunogram, a service that integrates multi-omic data sets into a single per patient view of key biomarker signatures specific to their own TME. Additionally, Veracyte, a unique multiplex tissue imaging and analysis approach, combines multiple technologies to characterize the tumor microenvironment. The company was founded in 2014 by Vincent Fert, who has been the CEO since 2014. | Health Technology |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Health Technology |
Alizé Pharma SARL | |
Société d'Amenagement des Territoires & d'Equipement des
Société d'Amenagement des Territoires & d'Equipement des Engineering & ConstructionIndustrial Services Société d'Amenagement des Territoires & d'Equipement des provides civil engineering construction work services. The private company is based in Saint-Paul-les-Dax, France. The French company was founded in 1963. The CEO is Olivier Martinez. | Industrial Services |